Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Sub-acute Inhalation Exposure to Aluminum Oxide Nanoparticles and its Effects on Wistar Rats as Opposed to the Micro-sized Chemical Analog

Author(s): Marina Aleksandrovna Zemlyanova*, Nina Vladimirovna Zaitseva, Mark Sergeevich Stepankov and Anna Mikhailovna Ignatova

Volume 12, Issue 5, 2024

Published on: 24 April, 2024

Page: [438 - 448] Pages: 11

DOI: 10.2174/0122117385258822230926043845

Price: $65

Abstract

Introduction: Aluminum oxide nanoparticles (Al2O3 NPs) are widely used in various productions. Simultaneously, many research works report the toxic effects of this nanomaterial. Given that, there is a growing risk of negative effects produced by Al2O3 NPs on public health.

Aims: This study aims to investigate the toxic effects of Al2O3 NPs as opposed to the micro-sized chemical analogue under sub-acute inhalation exposure.

Materials and Methods: We identified the physical properties of Al2O3 NPs as opposed to the micro- sized chemical analogue, including size, specific surface area, and total pore volume. Inhalation exposure to Al2O3 NPs was simulated on Wistar rats in a chamber for whole-body. The animals were exposed for 4 hours each day for 28 days. NPs and MPs concentrations in the chamber were kept at ~ 1/4000 from LC50. Rats’ behavior was examined prior to the exposure period and after it; after the last daily exposure, we examined biochemical and hematological blood indicators, NPs and MPs bioaccumulation, and pathomorphological changes in organ tissues.

Results: The tested Al2O3 sample is a nanomaterial according to its analyzed physical properties. Rats’ behavior changed more apparently under exposure to NPs compared to MPs. Aluminum levels, which were 1.62-55.20 times higher than the control, were identified in the lungs, liver, brain, and blood under exposure to NPs. These levels were also 1.55-7.65 times higher than the control under exposure to MPs. Biochemical indicators of rats’ blood also changed under exposure to NPs against the control. We identified more active ALT, AST, ALP, and LDH, elevated levels of GABA, MDA, and conjugated bilirubin, and a lower level of Glu. As opposed to exposure to MPs, ALT, AST, and ALP were more active; GABA and MDA levels were higher; Glu level was lower. Under exposure to NPs, the number of platelets grew, whereas no similar effect occurred under exposure to MPs. We established pathomorphological changes in tissues of the lungs, brain, heart, and liver under exposure to Al2O3 NPs; similar changes occurred only in the lungs under exposure to MPs. Exposure to NPs induced changes in tissue structures in a wider range of various organs, and these changes were more apparent than under exposure to MPs.

Conclusion: Greater toxicity of Al2O3 NPs as opposed to MPs is evidenced by a wider range of organs where their bioaccumulation occurs, more apparent pathomorphological and pathological functional changes. Established peculiarities of toxic effects produced by the analyzed nanomaterial should be considered when developing hygienic recommendations aimed at preventing and mitigating adverse impacts of Al2O3 NPs on human health under inhalation exposure.

« Previous Next »
Graphical Abstract

[1]
Khan I, Saeed K, Khan I. Nanoparticles: Properties, applications and toxicities. Arab J Chem 2019; 12(7): 908-31.
[http://dx.doi.org/10.1016/j.arabjc.2017.05.011]
[2]
Mobasser S, Firoozi AA. Review of nanotechnology applications in science and engineering. J Civ Eng Urban 2016; 6(4): 84-93.
[3]
Nowack B, Bucheli TD. Occurrence, behavior and effects of nanoparticles in the environment. Environ Pollut 2007; 150(1): 5-22.
[http://dx.doi.org/10.1016/j.envpol.2007.06.006] [PMID: 17658673]
[4]
Aluminium oxide nanoparticles market – Global industry analysis and forecast (2021-2027) by application, end-user and region. Maximize Market Research 2020.https://www.maximizemarketresearch.com/market-report/global-aluminium-oxide-nanoparticles-market/44118/
[5]
Piracha S, Saleem S. Nanoparticle: Role in chemical industries, potential sources and chemical catalysis applications. Sch Int J Chem Mater Sci 2021; 4(4): 40-5.
[http://dx.doi.org/10.36348/sijcms.2021.v04i04.006]
[6]
Shafiq M, Anjum S, Hano C, Anjum I, Abbasi BH. An overview of the applications of nanomaterials and nanodevices in the food industry. Foods 2020; 9(2): 148.
[http://dx.doi.org/10.3390/foods9020148] [PMID: 32028580]
[7]
Shafique M, Luo X. Nanotechnology in transportation vehicles: An overview of its applications, environmental, health and safety concerns. Materials 2019; 12(15): 2493.
[http://dx.doi.org/10.3390/ma12152493] [PMID: 31390752]
[8]
Salata OV. Applications of nanoparticles in biology and medicine. J Nanobiotechnology 2004; 2(1): 3.
[http://dx.doi.org/10.1186/1477-3155-2-3] [PMID: 15119954]
[9]
Liu X, Luo L, Ding Y, Xu Y. Amperometric biosensors based on aluminananoparticles-chitosan-horseradish peroxidase nanobiocomposites for the determination of phenolic compounds. Analyst 2011; 136(4): 696-701.
[http://dx.doi.org/10.1039/C0AN00752H] [PMID: 21127796]
[10]
Robertson TA, Sanchez WY, Roberts MS. Are commercially available nanoparticles safe when applied to the skin? J Biomed Nanotechnol 2010; 6(5): 452-68.
[http://dx.doi.org/10.1166/jbn.2010.1145] [PMID: 21329041]
[11]
Abed MS, Jawad ZA. Nanotechnology for defence application. In: Nanotechnology for electronic applications. Singapore: Springer Nature 2022.
[12]
Arul Prakash F, Dushendra Babu GJ, Lavanya M, Shenbaga Vidhya K, Devasena T. Toxicity studies of aluminium oxide nanoparticles in cell lines. Int J Nanotechnol Appl 2011; 5(2): 99-107.
[13]
Xie Y, Zhuang ZX. Chromium (VI)-induced production of reactive oxygen species, change of plasma membrane potential and dissipation of mitochondria membrane potential in Chinese hamster lung cell cultures. Biomed Environ Sci 2001; 14(3): 199-206.
[PMID: 11723719]
[14]
Lin W, Stayton I, Huang Y, Zhou XD, Ma Y. Cytotoxicity and cell membrane depolarization induced by aluminum oxide nanoparticles in human lung epithelial cells A549. Toxicol Environ Chem 2008; 90(5): 983-96.
[http://dx.doi.org/10.1080/02772240701802559]
[15]
Balasubramanyam A, Sailaja N, Mahboob M, Rahman MF, Hussain SM, Grover P. In vivo genotoxicity assessment of aluminium oxide nanomaterials in rat peripheral blood cells using the comet assay and micronucleus test. Mutagenesis 2009; 24(3): 245-51.
[http://dx.doi.org/10.1093/mutage/gep003] [PMID: 19237533]
[16]
Chen L, Yokel RA, Hennig B, Toborek M. Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J Neuroimmune Pharmacol 2008; 3(4): 286-95.
[http://dx.doi.org/10.1007/s11481-008-9131-5] [PMID: 18830698]
[17]
Bahadar H, Maqbool F, Niaz K, Abdollahi M. Toxicity of nanoparticles and an overview of current experimental models. Iran Biomed J 2016; 20(1): 1-11.
[http://dx.doi.org/10.7508/ibj.2016.01.001] [PMID: 26286636]
[18]
El-Hussainy EHMA, Hussein AM, Abdel-Aziz A, El-Mehasseb I. Effects of aluminum oxide (Al 2 O 3) nanoparticles on ECG, myocardial inflammatory cytokines, redox state, and connexin 43 and lipid profile in rats: Possible cardioprotective effect of gallic acid. Can J Physiol Pharmacol 2016; 94(8): 868-78.
[http://dx.doi.org/10.1139/cjpp-2015-0446] [PMID: 27191243]
[19]
Gregg S, Sing K. Adsorbtion, surface area and porosity. London: Academic Press Inc.M. 1982.
[20]
Barrett EP, Joyner LG, Halenda PP. The determination of pore volume and area distributions in porous substances. I. Computations from nitrogen isotherms. J Am Chem Soc 1951; 73(1): 373-80.
[http://dx.doi.org/10.1021/ja01145a126]
[21]
Barua S, Mitragotri S. Challenges associated with penetration of nanoparticles across cell and tissue barriers: A review of current status and future prospects. Nano Today 2014; 9(2): 223-43.
[http://dx.doi.org/10.1016/j.nantod.2014.04.008] [PMID: 25132862]
[22]
Huang YW, Cambre M, Lee HJ. The toxicity of nanoparticles depends on multiple molecular and physicochemical mechanisms. Int J Mol Sci 2017; 18(12): 2702.
[http://dx.doi.org/10.3390/ijms18122702] [PMID: 29236059]
[23]
Liu H, Zhang W, Fang Y, et al. Neurotoxicity of aluminum oxide nanoparticles and their mechanistic role in dopaminergic neuron injury involving p53-related pathways. J Hazard Mater 2020; 392: 122312.
[http://dx.doi.org/10.1016/j.jhazmat.2020.122312] [PMID: 32105957]
[24]
Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomed Sci 2008; 4(2): 89-96.
[PMID: 23675073]
[25]
Phaniendra A, Jestadi DB, Periyasamy L. Free radicals: Properties, sources, targets, and their implication in various diseases. Indian J Clin Biochem 2015; 30(1): 11-26.
[http://dx.doi.org/10.1007/s12291-014-0446-0] [PMID: 25646037]
[26]
Sirajuddin A, Raparia K, Lewis VA, et al. Primary pulmonary lymphoid lesions: Radiologic and pathologic findings. Radiographics 2016; 36(1): 53-70.
[http://dx.doi.org/10.1148/rg.2016140339] [PMID: 26761531]
[27]
Kaptein FHJ, Kroft LJM, Hammerschlag G, et al. Pulmonary infarction in acute pulmonary embolism. Thromb Res 2021; 202: 162-9.
[http://dx.doi.org/10.1016/j.thromres.2021.03.022] [PMID: 33862471]
[28]
Makarova VG, Makarova MN. Physiological, biochemical and biometric indicators to describe physiological norms in experimental animals: Reference book SPb. LEMA publishing house 2013; p. 116.
[29]
Kroll MH, Kharghan VA. Platelets in pulmonary vascular physiology and pathology. Pulm Circ 2012; 2(3): 291-308.
[http://dx.doi.org/10.4103/2045-8932.101398] [PMID: 23130099]
[30]
Al-Mufti F, Amuluru K, Smith B, et al. Emerging markers of early brain injury and delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage. World Neurosurg 2017; 107: 148-59.
[http://dx.doi.org/10.1016/j.wneu.2017.07.114] [PMID: 28755916]
[31]
Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med 2006; 354(4): 387-96.
[http://dx.doi.org/10.1056/NEJMra052732] [PMID: 16436770]
[32]
Sehba FA, Hou J, Pluta RM, Zhang JH. The importance of early brain injury after subarachnoid hemorrhage. Prog Neurobiol 2012; 97(1): 14-37.
[http://dx.doi.org/10.1016/j.pneurobio.2012.02.003] [PMID: 22414893]
[33]
Fujii M, Yan J, Rolland WB, Soejima Y, Caner B, Zhang JH. Early brain injury, an evolving frontier in subarachnoid hemorrhage research. Transl Stroke Res 2013; 4(4): 432-46.
[http://dx.doi.org/10.1007/s12975-013-0257-2] [PMID: 23894255]
[34]
Ciurea AV, Palade C, Voinescu D, Nica DA. Subarachnoid hemorrhage and cerebral vasospasm - literature review. J Med Life 2013; 6(2): 120-5.
[PMID: 23904869]
[35]
Claassen J, Bernardini GL, Kreiter K, et al. Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after subarachnoid hemorrhage: The Fisher scale revisited. Stroke 2001; 32(9): 2012-20.
[http://dx.doi.org/10.1161/hs0901.095677] [PMID: 11546890]
[36]
Tang WK, Wang L, Tsoi KKF, Barrash J, Kim JS. Personality changes after subarachnoid hemorrhage: A systematic review and meta-analysis. J Psychosom Res 2022; 156: 110762.
[http://dx.doi.org/10.1016/j.jpsychores.2022.110762] [PMID: 35220109]
[37]
Tang WK, Wang L, Kwok Chu Wong G, et al. Depression after subarachnoid hemorrhage: A systematic review. J Stroke 2020; 22(1): 11-28.
[http://dx.doi.org/10.5853/jos.2019.02103] [PMID: 32027789]
[38]
M’rad I, Jeljeli M, Rihane N, Hilber P, Sakly M, Amara S. Aluminium oxide nanoparticles compromise spatial learning and memory performance in rats. EXCLI Journal 2018; 17: 200-10.
[http://dx.doi.org/10.17179/excli2017-1050]
[39]
Mrad I, Sakly M, Amara S. Aluminum oxide nanoparticles induced cognitive deficits and oxidative stress in frontal cortex and cerebellum of rat. Adv J Toxicol: Curr Res 2017; 1(1): 7-14.
[40]
Celis ME, Torre E. Measurement of grooming behavior. Methods Neurosci 1993; 14: 378-88.
[http://dx.doi.org/10.1016/B978-0-12-185277-1.50029-0]
[41]
Petroff OAC. GABA and glutamate in the human brain. Neuroscientist 2002; 8(6): 562-73.
[http://dx.doi.org/10.1177/1073858402238515] [PMID: 12467378]
[42]
Nazarenko GI, Kishkun AA. Clinical evaluation of laboratory results. 20th ed. Moscow: Medicina 2006.

Rights & Permissions Print Cite
© 2025 Bentham Science Publishers | Privacy Policy